The price of Privia Health Group Inc (NASDAQ: PRVA) closed at $22.32 in the last session, up 2.01% from day before closing price of $21.88. In other words, the price has increased by $+0.44 from its previous closing price. On the day, 1294719 shares were traded.
Ratios:
We take a closer look at PRVA’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On February 22, 2024, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $21.
On December 06, 2023, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $27.JMP Securities initiated its Mkt Outperform rating on December 06, 2023, with a $27 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 25 when Sullivan William M sold 12,000 shares for $23.13 per share. The transaction valued at 277,560 led to the insider holds 5,452,533 shares of the business.
Sullivan William M sold 9,951 shares of PRVA for $229,172 on Jan 24. The Director now owns 5,464,533 shares after completing the transaction at $23.03 per share. On Dec 28, another insider, Sullivan William M, who serves as the Director of the company, sold 12,000 shares for $23.97 each. As a result, the insider received 287,640 and left with 5,474,484 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 2.58B and an Enterprise Value of 2.20B. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 120.52, and their Forward P/E ratio for the next fiscal year is 65.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 4.70. Its current Enterprise Value per Revenue stands at 1.33 whereas that against EBITDA is 81.01.
Stock Price History:
Over the past 52 weeks, PRVA has reached a high of $30.15, while it has fallen to a 52-week low of $19.17. The 50-Day Moving Average of the stock is 21.69, while the 200-Day Moving Average is calculated to be 23.69.
Shares Statistics:
According to the various share statistics, PRVA traded on average about 901.28K shares per day over the past 3-months and 1.23M shares per day over the past 10 days. A total of 118.22M shares are outstanding, with a floating share count of 101.63M. Insiders hold about 13.92% of the company’s shares, while institutions hold 96.41% stake in the company. Shares short for PRVA as of Feb 15, 2024 were 6.59M with a Short Ratio of 7.31, compared to 6.26M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.58% and a Short% of Float of 10.35%.
Earnings Estimates
The company has 12 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.03, while EPS last year was $0.06. The consensus estimate for the next quarter is $0.07, with high estimates of $0.11 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.38 and $0.14 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.36, with 13 analysts recommending between $0.58 and $0.23.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $721.51M. It ranges from a high estimate of $789.3M to a low estimate of $652.3M. As of the current estimate, Privia Health Group Inc’s year-ago sales were $658.9M, an estimated increase of 9.50% from the year-ago figure.
A total of 9 analysts have provided revenue estimates for PRVA’s current fiscal year. The highest revenue estimate was $3.29B, while the lowest revenue estimate was $2.81B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.84B, up 6.20% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $3.48B in the next fiscal year. The high estimate is $3.81B and the low estimate is $3.15B. The average revenue growth estimate for next year is up 15.40% from the average revenue estimate for this year.
